Negative 18 F-FES PET/CT Despite Estrogen Receptor Positivity by Immunohistochemistry.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40474373.
- Also identified by DOI 10.1097/RLU.0000000000006023.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunohistochemistry (IHC) is routinely used to determine the estrogen receptor (ER) expression status of breast cancer. 18 F-fluoro-estradiol ( 18 F-FES) PET/CT is indicated for select breast cancer patients with ER+ breast cancer, and patients with tracer-avid disease typically enjoy favorable responses to endocrine therapy (ET). We present 2 patients with metastatic breast cancer that were ER+ on IHC but lacked tracer avidity on 18 F-FES PET/CT. We hypothesize that despite ER detection on IHC, these receptors were nonfunctional, lacking the ability to bind estrogen. Since functional ER is a prerequisite for response to ET, these patients are not likely to respond to ET.
Medical subject headings
- Receptors, Estrogen
- Positron Emission Tomography Computed Tomography
- Breast Neoplasms
- Estradiol
- Positron-Emission Tomography